食品科学 ›› 2025, Vol. 46 ›› Issue (15): 194-190.doi: 10.7506/spkx1002-6630-20250225-129

• 营养卫生 • 上一篇    下一篇

基于网络药理学研究药食同源灵芝抗抑郁活性成分

寇融巍,杨心怡,何仰清,夏冰,刘俊超,赵贝塔,刘学波   

  1. (1.西安理工大学理学院,陕西 西安 710054;2.西北农林科技大学食品科学与工程学院,陕西 杨凌 712100)
  • 出版日期:2025-08-15 发布日期:2025-07-22
  • 基金资助:
    陕西省自然科学基础研究青年项目(2024JC-YBQN-0094); 陕西基础科学(化学、生物学)研究院基础科学研究计划项目(23JHQ037); 西安理工大学启动项目(109-451123005);陕西省重点产业链项目(2023-ZDLSF-06)

Evaluation of Antidepressant Compounds in Ganoderma lucidum Using Network Pharmacology

KOU Rongwei, YANG Xinyi, HE Yangqing, XIA Bing, LIU Junchao, ZHAO Beita, LIU Xuebo   

  1. (1. School of Science, Xi’an University of Technology, Xi’an 710054, China; 2. College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China)
  • Online:2025-08-15 Published:2025-07-22

摘要: 基于网络药理学方法和分子对接技术,系统预测灵芝中具有潜在抗抑郁功效的活性成分及其作用靶点与通路,并构建抑郁小鼠模型验证灵芝活性成分的抗抑郁功效与机制。结果表明,通过分析平台构建“灵芝-活性成分-交集靶点-抑郁”网络,从灵芝中筛选出赤芝酮A、赤芝酸Q甲酯和啤酒甾醇等19 个活性成分,以及AKT1、ESR1及白细胞介素(interleukin,IL)-6等122 个抗抑郁作用的靶点;核心活性成分可通过神经活性配体受体通路、神经退行性变-多种疾病通路、磷脂酰肌醇3-激酶/蛋白激酶B信号通路、环腺苷酸信号通路和丝裂原活化蛋白激酶信号通路等发挥抗抑郁作用;分子对接结果显示,灵芝核心活性成分赤芝酮A、赤芝酸Q甲酯和啤酒甾醇与关键靶蛋白的结合能均≤-7.0 kcal/mol,结合网络药理学结果,提示赤芝酮A可能具有潜在的抗抑郁效果。动物实验进一步证实,灵芝核心活性成分赤芝酮A可显著改善抑郁小鼠的行为异常、减轻脑组织神经元形态损伤,下调脑内单胺类神经递质的含量,并且显著抑制诱导型一氧化氮合酶、环氧合酶-2、肿瘤坏死因子-α、IL-6、IL-1β与IL-17等促炎因子的表达,从而发挥抗抑郁作用。本研究揭示了灵芝抗抑郁的多靶点、多通路作用机制,为其在功能性食品开发中的应用提供了科学依据。

关键词: 灵芝;抑郁;网络药理学;分子对接;作用机制

Abstract: Systematic prediction of potential antidepressant compounds in Ganoderma lucidum and their target proteins as well as related signaling pathways was carried out employing network pharmacology and molecular docking. A mouse model of depression was then used to validate the antidepression efficacy and mechanism of action of the bioactive compounds. Our network-based analysis identified a “G. lucidum-bioactive compounds-intersection target-depression” interaction network, revealing 19 active constituents, including lucidone A, methyl lucidente Q, and cerevisterol, as well as 122 antidepression-related targets, such as serine/threonine-protein kinase 1 (AKT1), estrogen receptor 1 (ESR1), and interleukin-6 (IL-6). The core active compounds were predicted to exert their antidepression effects through various pathways, including the neuroactive ligand-receptor interaction pathway, neurodegeneration-related pathways, the phosphatidylinositol 3-kinase/protein kinase B (PI3K-AKT) signaling pathway, the cyclic adenosine monophosphate (cAMP) signaling pathway, and the mitogen-activated protein kinase (MAPK) signaling pathway. Molecular docking analysis demonstrated that the binding affinities of the core active compounds of G. lucidum, lucidone A, methyl lucidente Q, and cerevisterol, to key target proteins were all ≤ -7.0 kcal/mol. The results of network pharmacology corroborated that lucidone A had potential antidepression activity. Animal experiments further confirmed that lucidone A significantly alleviated depression-like behaviors in mice, ameliorated neuronal morphological damage in brain tissue, and reduced neurotransmitter concentrations. Moreover, lucidone A markedly suppressed the expression of pro-inflammatory mediators, including inducible iinducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-α, IL-6, IL-1β, and IL-17, thereby exerting its antidepressant effect. These findings provide a scientific foundation for the application of G. lucidum in functional food development.

Key words: Ganoderma lucidum; depression; network pharmacology; molecular docking; mechanism of action

中图分类号: